• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Actoxumab + bezlotoxumab combination: what promise for Clostridium difficile treatment?
【24h】

Actoxumab + bezlotoxumab combination: what promise for Clostridium difficile treatment?

机译：Actoxumab + Bezlotoxumab组合：梭菌艰难术治疗的承诺是什么？

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Clostridium difficile infection (CDI) is the most common healthcare-associated infection worldwide. As standard CDI antibiotic therapies can result in unacceptably high recurrence rates, novel therapeutic strategies for CDI are necessary. A recently emerged immunological therapy is a monoclonal antibody against C. difficile toxin B. Areas covered: In this review, the authors summarize the available pharmacological, preclinical, and clinical data for the CDI treatment based on anti-toxin A (actoxumab) and anti-toxin B (bezlotoxumab) human monoclonal antibodies (HuMabs), and discuss about the potentiality of a therapy that includes HuMab combined administration for CDI. Expert opinion: Although only bezlotoxumab is indicated to reduce recurrence of CDI, experimental studies using a combination of HuMabs actoxumab and bezlotoxumab have shown that bolstering the host immune response against both the C. difficile toxins may be effective in primary and secondary CDI prevention. Besides neutralizing both the key virulence factors, combination of two HuMabs could potentially offer an advantage for a yet to emerge C. difficile strain, which is a steady threat for patients at high risk of CDI. However, as actoxumab development was halted, passive immunotherapy with actoxumab/bezlotoxumab is actually impracticable. Future research will be needed to assess HuMab combination as a therapeutic strategy in clinical and microbiological cure of CDI.
机译：简介：梭菌差异感染（CDI）是全球最常见的医疗保健相关感染。随着标准CDI抗生素疗法可能导致不可接受的高复发率，需要新的CDI治疗策略。最近出现的免疫疗法是针对C.艰难毒素的单克隆抗体。涵盖的地区：在本综述中，基于抗毒素A（Actoxumab）和抗体总结了CDI治疗的可用药理学，临床前和临床数据。 -Toxinb（Bezlotoxumab）人单克隆抗体（Humabs），并讨论了包括Humab联合CDI施用的治疗的潜力。专家意见：尽管仅表明Bezlotoxumab减少CDI的复发，但是使用Humabs Actoxumab和Bezlotoxumab的组合的实验研究表明，对C.艰难梭菌的宿主免疫应答膨胀型在初级和二级CDI预防中有效。除了中和关键的毒力因子外，两个Humabs的组合可能会提供尚未出现的艰难梭菌菌株的优势，这对于高风险的患者来说是一种稳定的威胁。然而，随着Actoxumab的开发被停止，与Actoxumab / Bezlotoxumab的被动免疫疗法实际上是不切实际的。需要将来的研究评估Humab组合作为CDI临床和微生物治疗的治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号